Champions Oncology Q3 Adj $(0.16) Misses $(0.15) Estimate, Sales $12.02M Miss $13.48M Estimate
Portfolio Pulse from Benzinga Newsdesk
Champions Oncology (NASDAQ:CSBR) reported Q3 losses of $(0.16) per share, missing the $(0.15) estimate, and sales of $12.02M, missing the $13.48M estimate. This represents a 6.67% miss on EPS and a 10.84% miss on sales, with a 5.90% decrease in sales compared to the same period last year.
March 12, 2024 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Champions Oncology reported a Q3 loss of $(0.16) per share, missing estimates, and sales of $12.02M, also below expectations.
Missing both earnings and sales estimates typically leads to negative investor sentiment in the short term. The reported decrease in sales compared to the previous year further compounds the negative outlook, suggesting potential challenges in the company's operations or market conditions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100